Cerus Reports Q3 2026 Revenue Growth Driven by INTERCEPT Fibrinogen Complex
Cerus (CERS) reported third-quarter revenue of $64.0 million, with product revenue rising 10% year-over-year to $57.7 million. This growth was primarily fueled by strong sales of the INTERCEPT Fibrinogen Complex (ISC), which saw an 80% increase in dose-equivalent volume, and robust performance in the North American platelet market. The company achieved its tenth consecutive quarter of positive non-GAAP adjusted EBITDA, totaling $5.7 million. While inflationary pressures and currency fluctuations slightly compressed product gross margins to 52.4%, Cerus reaffirmed its full-year 2026 product revenue guidance of $229 million to $231 million. Clinical updates included meeting the primary efficacy endpoint for the RBC Phase III REDeS study, though the company adjusted its expected CE Mark timeline to late 2027. Additionally, management noted that while government contract revenue declined due to winding down older contracts, unit placements for the INT200 illumination device exceeded expectations.
Tickers: $CERS
Topics: Clinical Trial Results EBITDA Product Performance Revenue Growth